The 52-Week Low Club for Monday

Photo of Paul Ausick
By Paul Ausick Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Stock PriceApril 11, 2016: Here are four stocks trading with relatively heavy volume among 21 equities making new 52-week lows in Monday’s session. The day’s NYSE winners led losers by about 3-to-2. Nasdaq winners to losers were essentially even at the bell.

Under Armour Inc. (NYSE: UA) posted a new 52-week low on Monday. Shares traded at a low of $41.00, down about 5.8%, after closing at $43.54 on Friday. The stock’s 52-week high is $105.89. Volume totaled more than 3 times the daily average of around 4 million shares. Analysts at Morgan Stanley had so woeful words on sale, including a drop of 7% in women’s apparel sales.

Endo International plc (NASDAQ: ENDP) fell by about 9.3% on Monday to post a new 52-week low of $25.67 against a high of $96.58. The stock closed at $28.30 on Friday night. Volume totaled  more than 10 million shares, more than 50% above the daily average of about 6.3 million. The drugmaker suffered from a knock-on effect following Insys’s announcement of lower sales for its opioid painkiller.

Allergan plc (NYSE: AGN) dropped about 4.4% on Monday to post a new 52-week low of $225.60 against a 52-week high of $340.34. The stock closed at $236.00 on Friday night. Volume was nearly double the stock’s daily average volume of around 4.1 million. Chatter suggest that the company might try to soothe its bruises from the busted deal with Pfizer buy making an offer for Endo. That makes little sense because Allergan is selling its stake in generics maker Teva, and Endo gets half or more of its sales from generics.

[recirclink id=324516]

Clovis Oncology Inc. (NASDAQ: CLVS) dropped about 8.8% on Monday to post a new 52-week low at $14.38 after closing at $15.77 on Friday. The stock’s 52-week high is $116.75. Share volume of around 4 million was more than 3 times the daily average of about 1.3 million shares traded. Reuters reported that FDA reviewers want the company’s new cancer drug to carry a black-box warning.

Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for a673b.bigscoots-temp.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618